ArticleMolecular psychiatry2026
Genetic and epigenetic analysis of plasma glial fibrillary acidic protein (GFAP) levels in PTSD.
Article in Molecular psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Large-Scale Data Analysis of Post-Traumatic Stress Disorder (PTSD) Through GWAS Fine-Mapping and Systems Biology.Journal of personalized medicine · 2026Article
- Epigenetic mechanisms in traumatic brain injury: a focus on astrocytes and therapeutic implications.Journal of neuroinflammation · 2026Review
- Combined plasma and imaging biomarkers as predictors of neurological outcome in cervical traumatic spinal cord injury.BMC neurology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Glial fibrillary acidic protein (GFAP) is an astrocytic marker that can be assessed in blood using single molecule array technology. Recent studies suggest that individuals with posttraumatic stress disorder (PTSD) have suppressed circulating levels of this CNS biomarker. This study examined the hypothesis that PTSD and plasma GFAP levels share common genetic and epigenetic pathways. Using data from 1096 veterans and civilians, we computed a PTSD polygenic risk score (PRS) derived from a prior PTSD genomewide association study (GWAS) and found that PTSD severity and the PRS were each associated with reduced levels of GFAP. To clarify the basis of the PRS association, we performed a GWAS of GFAP which identified 20 genomewide-significant loci including genes implicated in independent GWASs of PTSD and neurodegenerative disease (e.g., PRKN, NFIA). Comparison of the PTSD and GFAP GWAS results showed that PTSD-associated genes were significantly enriched in the GFAP results with notable overlap involving NPSR1 and the protocadherin alpha (PCDHA) gene cluster. Similarly, we performed an epigenomewide association study (EWAS) of GFAP, which identified 4 genomewide-significant associations (including loci in MCT4 and SREBF1) and then compared those results to the findings of a PTSD EWAS. Results again showed significantly greater overlap than would be expected by chance and included loci implicated in prior studies of depression, dementia, and inflammation. This study clarifies the genetic and epigenetic basis of the association between PTSD and plasma GFAP levels and should encourage future research into the role of GFAP in the pathophysiology of PTSD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.